The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout
Open accessAbstract
Objective.: To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout. Methods.: Subjects (n = 1086) in this open-label extension study were assigned to fixed-dose daily urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 mg). ULT reassignment was permitted during months 1 to 6 to achieve serum urate (SUA) concentrations between 3.0 and < 6.0 mg/dl. Flares requiring treatment, tophus size, safety, and SUA levels were monitored during up to 40 months of ULT maintenance. Results.: After 1 month initial treatment, > 80% of subjects receiving either febuxostat dose, but only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl compared with subjects receiving febuxostat. Maintenance of SUA < 6.0 mg/dl resulted in progressive reduction to nearly 0 in proportion of subjects requiring gout flare treatment. Baseline tophus resolution was achieved by 46%, 36%, and 29% of subjects maintained on febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respectively. Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups. Conclusion.: Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Registered as NCT00175019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Febuxostat was approved in 2008 in Europe and by the Food and Drug Administration in 2009 for the treatment of gout (commercial name Uloric in United States, Adenuric in Europe) (76, 77, 837).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., McCarty, D. J., & Yű, T.-F. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,433
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V., Conaghan, P. G., Gerster, J., Jacobs, J. W. G., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,406
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Self-citationHande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 679
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citationEffect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Pérez-Ruiz, F., Calabozo, M., Pijoán, J. I., Herrero-Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 455
Shoji, A., Yamanaka, H., & Kamatani, N. (2004) · Arthritis Care & Research · doi:10.1002/art.20405 · Cited by 439
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
Takano, Y., Hase-Aoki, K., Horiuchi, H., Zhao, L., Kasahara, Y., Kondo, S., & Becker, M. A. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.031 · Cited by 339
Self-citationSarawate, C. A., Brewer, K., Yang, W., Patel, P., Schumacher, H. R., Saag, K. G., & Bakst, A. W. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.925 · Cited by 293
Self-citationPérez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A. M., Erauzkin, G. G., & Ruiz-Lucea, E. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.9.545 · Cited by 258
Cited by
Sorted by citations
Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Pérez-Ruiz, F., & Stamp, L. K. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0115-y · Cited by 728
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Becker, M. A., Schumacher, H. R., Espinoza, L. R., Wells, A. F., MacDonald, P., Lloyd, E., & Lademacher, C. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2978 · Cited by 526
Self-citationLongitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome
Mars, R. A. T., Yang, Y., Ward, T., Houtti, M., Priya, S., Lekatz, H. R., Tang, X., Sun, Z., Kalari, K. R., Korem, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.007 · Cited by 456
“Hypoxanthine is an appealing drug target given the availability of the xanthine oxidase inhibitor allopurinol, which is used to treat gout (Becker et al., 2009), and thiopurines, which are used to optimize inflammatory bowel disease therapy (Moreau et al.”
Mackenzie, I. S., Ford, I., Nuki, G., Hallas, J., Hawkey, C. J., Webster, J., Ralston, S. H., Walters, M., Robertson, M., Caterina, R. D., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32234-0 · Cited by 372
Metadata
- Authors
- BECKER, M. A., SCHUMACHER, H. R., MacDONALD, P. A., LLOYD, E., & LADEMACHER, C.
- Affiliations
- University of Chicago (US)
- University of Pennsylvania (US)
- Takeda (Japan) (JP)
- ORCID
- BECKER, MICHAEL A.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2009-03-13
- Volume
- 36
- Issue
- 6
- Pages
- 1273-1282
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2145066076
- Cited by
- 269
- References
- 23
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 21 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 15 · 2014: 24 · 2013: 20 · 2012: 15
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Rheumatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- gout, febuxostat, allopurinol, urate-lowering therapy, serum uric acid, gout flares, long-term maintenance therapy, cardiovascular adverse events, drug safety
- MeSH terms
- Febuxostat, Allopurinol, Gout, Gout Suppressants, Thiazoles, Uric Acid, Treatment Outcome, Hyperuricemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
